Tiny study probes GIP's role in gut blood flow for diabetes
NCT ID NCT06426823
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at how the hormone GIP changes blood flow in the gut after a sugary drink in 10 people with type 2 diabetes. Researchers used a GIP-blocking drug to see what happens when GIP is stopped. The goal was to better understand GIP's role in digestion and metabolism, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GIP(3-30)NH2 (a GIP receptor blocker) and saline placebo
What this could lead to
If successful, this could clarify how GIP influences digestion and metabolism in type 2 diabetes, potentially guiding future treatments.
What could go wrong
This is a very small, completed study (10 people) focused on understanding basic mechanisms, not testing a treatment. Results may not apply broadly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLOOD FLOW are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rigshospitalet
Copenhagen, 2200, Denmark